July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Amol Akhade: Landmark Advance in Gastric Cancer – Phase 3 FORTITUDE-101 Trial Positive for Bemarituzumab
Jul 1, 2025, 08:31

Amol Akhade: Landmark Advance in Gastric Cancer – Phase 3 FORTITUDE-101 Trial Positive for Bemarituzumab

Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on LinkedIn:

“Landmark Advance in Gastric Cancer: Phase 3 FORTITUDE-101 Trial Positive for Bemarituzumab. Amgen has announced that the Phase 3 FORTITUDE-101 trial has met its primary OS endpoint at interim analysis.

The study evaluated bemarituzumab plus mFOLFOX6 versus chemotherapy alone in first-line treatment of locally advanced or metastatic gastric/GEJ cancer with FGFR2b overexpression (HER2-negative).

Key Highlights: Statistically significant and clinically meaningful overall survival (OS) benefit FGFR2b+ defined as IHC 2+/3+ in ≥10% of tumor cells ~24% of gastric/GEJ adenocarcinomas qualify as FGFR2b+ Represents a first-in-class targeted therapy opportunity in this subset

Safety Profile: Despite the efficacy, ocular toxicity emerged as a notable concern:

Dry eye, keratitis, reduced visual acuity, and corneal epithelial damage These events were more frequent and more severe in the bemarituzumab arm Findings are consistent with Phase 2 and may require proactive ophthalmologic monitoring

This side-effect profile will play a key role in determining real-world uptake and treatment compliance.

Broader Context: FGFR2b is now emerging as a clinically actionable biomarker in gastric cancer, alongside HER2 and PD-L1. The results of FORTITUDE-101 support integrating routine IHC testing for FGFR2b in the diagnostic workup for advanced disease.

Additionally, new agents in development—including FGFR2b-targeted ADCs—are exploring alternative approaches that may improve the efficacy–toxicity balance in this space.

Clinical Implications:

  1. FGFR2b+ patients (~1 in 4) now have a promising biomarker-guided first-line option
  2. Ocular toxicity is real and needs early, multidisciplinary management
  3. FGFR2b IHC testing may soon become standard practice
  4. The gastric cancer landscape is shifting toward precision-driven segmentation

Are you ready to test for FGFR2b in clinic? How would you counsel patients on eye toxicity? Is this the beginning of a new biomarker era in GI oncology?”

Amol Akhade: Landmark Advance in Gastric Cancer - Phase 3 FORTITUDE-101 Trial Positive for Bemarituzumab

More posts featuring Amol Akhade.